Viking Therapeutics Advances Late-Stage Clinical Trials for VK2735
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 4 days ago
0mins
Source: stocktwits
- Trial Enrollment Completed: Viking announced that its late-stage clinical trial for VK2735 has enrolled approximately 1,000 patients with type 2 diabetes, aiming for significant weight loss over 78 weeks, which is expected to positively impact future drug approvals.
- Drug Development Outlook: Viking plans to advance the oral version of VK2735 into late-stage studies in Q3 2026, with CEO stating that the company will have four late-stage trials by the end of 2026, demonstrating confidence in its development pipeline.
- Market Sentiment Improvement: Viking's stock rose 3% on Thursday amid speculation of a potential buyout and FDA approval, with retail investor sentiment shifting from 'bearish' to 'neutral', indicating increased confidence in the company's future prospects.
- Competitive Advantage Analysis: VK2735 is dubbed the “Ozempic killer” and has the potential to dethrone Eli Lilly's products in the obesity drug market, while Viking also plans to file for trials of a novel amylin agonist this quarter to further expand its obesity drug portfolio.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy VKTX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on VKTX
Wall Street analysts forecast VKTX stock price to rise
12 Analyst Rating
12 Buy
0 Hold
0 Sell
Strong Buy
Current: 29.920
Low
70.00
Averages
97.00
High
125.00
Current: 29.920
Low
70.00
Averages
97.00
High
125.00
About VKTX
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company that is focused on the development of therapies for the treatment of metabolic and endocrine disorders. Its clinical programs include VK2735, a novel dual agonist of the glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide receptors for the potential treatment of various metabolic disorders. It is evaluating an oral formulation of VK2735 in a Phase II trial. It is also developing VK2809, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of lipid and metabolic disorders. Its newest program is evaluating a series of internally developed dual amylin and calcitonin receptor agonists for the treatment of obesity and other metabolic disorders. In the rare disease space, it is developing VK0214, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the potential treatment of X-linked adrenoleukodystrophy.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Investment Opportunities in the Healthcare Sector
- Viking Therapeutics Outlook: Viking Therapeutics has completed enrollment for its pivotal phase 3 trial of VK2735, with results expected next year, and analysts believe its stock could rise by over 60% in the coming year, with some predicting a price target exceeding $107 per share due to its leading position in obesity drug development.
- HCA Healthcare Growth Potential: HCA Healthcare operates 186 hospitals and approximately 2,400 outpatient facilities in the U.S., with same-facility admissions rising 2.4% year-over-year in Q4 2025, contributing to nearly 7% revenue growth, and management anticipates a 6% increase in annual revenue this year, driven by an aging population.
- Aging Population Drives Medical Demand: The 2020 census reported 55.8 million people aged 65 and older, accounting for 17% of the population, with projections estimating this will rise to 71.6 million by 2030, comprising 20.7% of the population, thereby increasing demand for HCA's healthcare services and strengthening its market position.
- AI Technology Enhances Operational Efficiency: HCA is leveraging its Timpani platform to improve nurse staffing through artificial intelligence, addressing bottlenecks in the U.S. healthcare system, and this forward-looking management strategy is expected to enhance service quality and operational efficiency, thereby increasing its long-term investment appeal.
See More
Investment Opportunities in Biotech and Healthcare Systems
- Biotech Potential: Viking Therapeutics has completed enrollment in a crucial phase 3 trial for its VK2735 drug, with results expected next year; analysts predict a stock price target between $107 and $125, indicating strong market potential if approved.
- Healthcare System Growth: HCA Healthcare operates 186 hospitals and 2,400 outpatient facilities in the U.S., with same-facility admissions rising 2.4% year-over-year in Q4 2025, boosting overall revenue by nearly 7% to $19.5 billion, showcasing its market advantage amid an aging population.
- Demographic Trends Impact: The 2020 census reported 55.8 million people aged 65 and older, making up 17% of the population, projected to rise to 71.6 million by 2030, comprising 20.7%, which will further drive demand for HCA's healthcare services, creating long-term growth momentum.
- AI Technology Application: HCA is leveraging its Timpani platform to improve nurse staffing through artificial intelligence, addressing bottlenecks in the U.S. healthcare system; while some market analysts are cautious about a 60% stock price increase, its long-term investment value remains significant.
See More
Viking and Structure Intensify Competition in Obesity Drug Development
- Clinical Trial Progress: Viking announced the enrollment of approximately 1,000 patients with obesity or overweight type 2 diabetes in the late-stage trial of VK2735, with a primary endpoint assessing weight change after 78 weeks, which could significantly enhance its market competitiveness if successful.
- Significant Drug Efficacy: In a mid-stage trial, VK2735 achieved a mean weight loss of 14.7% in 13 weeks, establishing a solid foundation for its subsequent clinical development and potentially attracting more investor interest.
- Market Potential: According to Koyfin, GPCR stock has a 12-month target of $109, implying a 147.95% upside, while VKTX's target is $92.72, representing a 209.80% upside, indicating strong prospects for both companies in the obesity drug market.
- Investor Sentiment Shift: While VKTX stock has risen 24% this year, GPCR has surged 154%, reflecting differing market perceptions, with VKTX sentiment remaining neutral and GPCR appearing more bearish.
See More
Viking Therapeutics: A Dark Horse in the GLP-1 Market
- Market Potential: The GLP-1 weight loss market is projected to reach annual sales of $100 billion by the next decade, presenting a significant growth opportunity for Viking Therapeutics and its VK2735 candidate, especially with the potential launch of an oral version.
- Clinical Trial Progress: The injectable version of VK2735 is currently in phase 3 clinical trials, while the oral version completed phase 2 trials last year with highly promising initial results, laying a solid foundation for future commercialization.
- Acquisition Potential: Should VK2735 achieve commercial viability, Viking could become a takeover target in the biotech sector, with acquisition offers potentially reaching three times its current $4 billion market cap, reflecting strong market expectations for its future.
- Investment Risks and Opportunities: Viking's stock presents a binary risk, where the success or failure of VK2735 will directly impact its share price; despite the high risks, the potential rewards are equally substantial, necessitating careful position sizing by investors to navigate possible volatility.
See More
Viking Therapeutics' VK2735: A Dark Horse in GLP-1 Weight Loss Market
- Significant Market Potential: The GLP-1 weight loss market is projected to reach annual sales of $100 billion by the next decade, providing Viking Therapeutics' VK2735 with substantial market opportunities, particularly with the promising results expected from its oral version's clinical trials.
- Critical Clinical Trial Phase: The injectable VK2735 is currently in phase 3 clinical trials, while the oral version's phase 2 trial completed last year with promising initial results, which will directly impact Viking's stock performance depending on the outcomes of these trials.
- Acquisition Potential: Should VK2735 achieve commercial viability, Viking's market cap of approximately $4 billion could attract acquisition offers potentially reaching three times its current valuation, highlighting its appeal as a biotech stock.
- Risks and Opportunities: While the outlook for VK2735 is optimistic, the stock carries significant volatility risks; Viking's shares once approached $100 but currently trade around $32, necessitating careful risk-reward assessment by investors.
See More
Viking Therapeutics Advances Late-Stage Clinical Trials for VK2735
- Trial Enrollment Completed: Viking announced that its late-stage clinical trial for VK2735 has enrolled approximately 1,000 patients with type 2 diabetes, aiming for significant weight loss over 78 weeks, which is expected to positively impact future drug approvals.
- Drug Development Outlook: Viking plans to advance the oral version of VK2735 into late-stage studies in Q3 2026, with CEO stating that the company will have four late-stage trials by the end of 2026, demonstrating confidence in its development pipeline.
- Market Sentiment Improvement: Viking's stock rose 3% on Thursday amid speculation of a potential buyout and FDA approval, with retail investor sentiment shifting from 'bearish' to 'neutral', indicating increased confidence in the company's future prospects.
- Competitive Advantage Analysis: VK2735 is dubbed the “Ozempic killer” and has the potential to dethrone Eli Lilly's products in the obesity drug market, while Viking also plans to file for trials of a novel amylin agonist this quarter to further expand its obesity drug portfolio.
See More
Investment Opportunities in the Healthcare Sector
- Viking Therapeutics Outlook: Viking Therapeutics has completed enrollment for its pivotal phase 3 trial of VK2735, with results expected next year, and analysts believe its stock could rise by over 60% in the coming year, with some predicting a price target exceeding $107 per share due to its leading position in obesity drug development.
- HCA Healthcare Growth Potential: HCA Healthcare operates 186 hospitals and approximately 2,400 outpatient facilities in the U.S., with same-facility admissions rising 2.4% year-over-year in Q4 2025, contributing to nearly 7% revenue growth, and management anticipates a 6% increase in annual revenue this year, driven by an aging population.
- Aging Population Drives Medical Demand: The 2020 census reported 55.8 million people aged 65 and older, accounting for 17% of the population, with projections estimating this will rise to 71.6 million by 2030, comprising 20.7% of the population, thereby increasing demand for HCA's healthcare services and strengthening its market position.
- AI Technology Enhances Operational Efficiency: HCA is leveraging its Timpani platform to improve nurse staffing through artificial intelligence, addressing bottlenecks in the U.S. healthcare system, and this forward-looking management strategy is expected to enhance service quality and operational efficiency, thereby increasing its long-term investment appeal.
See More
Investment Opportunities in Biotech and Healthcare Systems
- Biotech Potential: Viking Therapeutics has completed enrollment in a crucial phase 3 trial for its VK2735 drug, with results expected next year; analysts predict a stock price target between $107 and $125, indicating strong market potential if approved.
- Healthcare System Growth: HCA Healthcare operates 186 hospitals and 2,400 outpatient facilities in the U.S., with same-facility admissions rising 2.4% year-over-year in Q4 2025, boosting overall revenue by nearly 7% to $19.5 billion, showcasing its market advantage amid an aging population.
- Demographic Trends Impact: The 2020 census reported 55.8 million people aged 65 and older, making up 17% of the population, projected to rise to 71.6 million by 2030, comprising 20.7%, which will further drive demand for HCA's healthcare services, creating long-term growth momentum.
- AI Technology Application: HCA is leveraging its Timpani platform to improve nurse staffing through artificial intelligence, addressing bottlenecks in the U.S. healthcare system; while some market analysts are cautious about a 60% stock price increase, its long-term investment value remains significant.
See More
Viking and Structure Intensify Competition in Obesity Drug Development
- Clinical Trial Progress: Viking announced the enrollment of approximately 1,000 patients with obesity or overweight type 2 diabetes in the late-stage trial of VK2735, with a primary endpoint assessing weight change after 78 weeks, which could significantly enhance its market competitiveness if successful.
- Significant Drug Efficacy: In a mid-stage trial, VK2735 achieved a mean weight loss of 14.7% in 13 weeks, establishing a solid foundation for its subsequent clinical development and potentially attracting more investor interest.
- Market Potential: According to Koyfin, GPCR stock has a 12-month target of $109, implying a 147.95% upside, while VKTX's target is $92.72, representing a 209.80% upside, indicating strong prospects for both companies in the obesity drug market.
- Investor Sentiment Shift: While VKTX stock has risen 24% this year, GPCR has surged 154%, reflecting differing market perceptions, with VKTX sentiment remaining neutral and GPCR appearing more bearish.
See More
Viking Therapeutics: A Dark Horse in the GLP-1 Market
- Market Potential: The GLP-1 weight loss market is projected to reach annual sales of $100 billion by the next decade, presenting a significant growth opportunity for Viking Therapeutics and its VK2735 candidate, especially with the potential launch of an oral version.
- Clinical Trial Progress: The injectable version of VK2735 is currently in phase 3 clinical trials, while the oral version completed phase 2 trials last year with highly promising initial results, laying a solid foundation for future commercialization.
- Acquisition Potential: Should VK2735 achieve commercial viability, Viking could become a takeover target in the biotech sector, with acquisition offers potentially reaching three times its current $4 billion market cap, reflecting strong market expectations for its future.
- Investment Risks and Opportunities: Viking's stock presents a binary risk, where the success or failure of VK2735 will directly impact its share price; despite the high risks, the potential rewards are equally substantial, necessitating careful position sizing by investors to navigate possible volatility.
See More
Viking Therapeutics' VK2735: A Dark Horse in GLP-1 Weight Loss Market
- Significant Market Potential: The GLP-1 weight loss market is projected to reach annual sales of $100 billion by the next decade, providing Viking Therapeutics' VK2735 with substantial market opportunities, particularly with the promising results expected from its oral version's clinical trials.
- Critical Clinical Trial Phase: The injectable VK2735 is currently in phase 3 clinical trials, while the oral version's phase 2 trial completed last year with promising initial results, which will directly impact Viking's stock performance depending on the outcomes of these trials.
- Acquisition Potential: Should VK2735 achieve commercial viability, Viking's market cap of approximately $4 billion could attract acquisition offers potentially reaching three times its current valuation, highlighting its appeal as a biotech stock.
- Risks and Opportunities: While the outlook for VK2735 is optimistic, the stock carries significant volatility risks; Viking's shares once approached $100 but currently trade around $32, necessitating careful risk-reward assessment by investors.
See More
Viking Therapeutics Advances Late-Stage Clinical Trials for VK2735
- Trial Enrollment Completed: Viking announced that its late-stage clinical trial for VK2735 has enrolled approximately 1,000 patients with type 2 diabetes, aiming for significant weight loss over 78 weeks, which is expected to positively impact future drug approvals.
- Drug Development Outlook: Viking plans to advance the oral version of VK2735 into late-stage studies in Q3 2026, with CEO stating that the company will have four late-stage trials by the end of 2026, demonstrating confidence in its development pipeline.
- Market Sentiment Improvement: Viking's stock rose 3% on Thursday amid speculation of a potential buyout and FDA approval, with retail investor sentiment shifting from 'bearish' to 'neutral', indicating increased confidence in the company's future prospects.
- Competitive Advantage Analysis: VK2735 is dubbed the “Ozempic killer” and has the potential to dethrone Eli Lilly's products in the obesity drug market, while Viking also plans to file for trials of a novel amylin agonist this quarter to further expand its obesity drug portfolio.
See More
